Research programme: ulcerative colitis therapeutic - BenevolentAI
Alternative Names: Ulcerative colitis - BenevolentAILatest Information Update: 28 Nov 2025
At a glance
- Originator BenevolentAI
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Ulcerative colitis
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Ulcerative-colitis in United Kingdom (PO)
- 19 Oct 2021 Research programme: ulcerative colitis therapeutic - BenevolentAI is available for licensing as of 19 Oct 2021. https://www.benevolent.com/partnering
- 14 Oct 2021 Preclinical trials in Ulcerative colitis in United Kingdom (PO) .